'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies.
莫菲特癌症中心今天宣布与阿斯利康展开战略合作，旨在加速细胞疗法，尤其是嵌合抗原受体T细胞（CAR T细胞）和T细胞受体（TCR T细胞）疗法的发展。
Under this collaboration, AstraZeneca will have priority access to Moffitt's leading clinical environment and forge strong connections between physician-scientists to accelerate the investigation of novel cell therapies.
在这次合作中，阿斯利康将优先获得莫菲特领先的临床环境，并在医学科学家之间建立紧密联系，加快对新型细胞疗法的研究。
Advances in cell therapy, including CAR Ts and TCR Ts, are reshaping cancer care by offering potential new treatments for cancers with limited treatment options. The field has grown exponentially since the first CAR T therapies were approved in 2017. Moffitt was pivotal in the clinical trials that led to several FDA approvals for cell therapies and continues to grow its capabilities in this field, with an extensive network of cancer centers across the United States.
细胞疗法，包括CAR T和TCR T，正在重新定义癌症护理，为治疗选择有限的癌症患者提供潜在的新治疗方法。这个领域自2017年首个CAR T疗法获得批准以来，发展迅猛。莫菲特在导致多种FDA批准细胞疗法的临床试验中扮演了关键角色，并且在这个领域不断扩大其能力，拥有遍布全美的癌症中心网络。
The collaboration aims to address cell therapy development challenges and expand cell therapies' reach to more patients in the United States and beyond. A key focus will be on advancing clinical studies to investigate cell therapies in solid tumors and further optimizing clinical operations to streamline and expedite the delivery of autologous cell therapies to patients.
合作旨在应对细胞疗法研发的挑战，将细胞疗法的覆盖面扩大到更多美国及其他地区的患者。其中一个关键焦点是推动临床研究，以探索在实体肿瘤中应用细胞疗法，并进一步优化临床运作，以便更高效地将自体细胞疗法交付给患者。
"We are excited to collaborate with AstraZeneca to push the boundaries of what's possible in cancer treatment. By combining our clinical expertise with AstraZeneca's innovative pipeline of investigational cell therapies, global footprint and leadership in oncology, we aim to bring potential new cell therapies to patients faster and more efficiently," said Patrick Hwu, M.D., president and CEO of Moffitt.
莫菲特的总裁兼首席执行官Patrick Hwu 万.D表示：“我们很高兴与阿斯利康合作，推动癌症治疗的可能性。通过将我们的临床专业知识与阿斯利康创新的细胞疗法管线、全球影响力和肿瘤学领域领导地位相结合，我们旨在更快、更高效地为患者带来潜在的新型细胞疗法。”
"This collaboration will strengthen our connections with the Moffitt Cancer Center to accelerate the development of our autologous cell therapy pipeline as we strive to redefine cancer treatment for more people living with hematological and solid cancers," said Carsten Linnemann, Head of Oncology Cell Therapy Clinical Development, AstraZeneca.
阿斯利康肿瘤学细胞疗法临床开发负责人Carsten Linnemann表示：“这次合作将加强我们与莫菲特癌症中心的联系，加速我们自体细胞疗法管线的发展，为更多患有血液和实体肿瘤的人重新定义癌症治疗。”